Scientists have determined that AMD3100, originally developed in acquired immune deficiency syndrome treatment, could markedly inhibit spreading of colorectal cancer cells by blocking a new pair of ligands and its unique receptor. This effect differs from the usual inhibition by a conventional chemotherapic agent that is more specific to cancer cells with high metastatic potential.